Polycythemia vera syndrome--as a protrombothic state

Area of Science:

• Hematology
• Cardiovascular Medicine

Background:

• Polycythemia vera (PV) is a myeloproliferative neoplasm associated with an increased risk of thrombotic events.
• The prothrombotic state in PV is multifactorial, involving both genetic and acquired factors.
• Cardiovascular disease (CVD) can exacerbate the thrombotic risk in PV patients.

Purpose of the Study:

• To investigate coagulation and fibrinolysis factor disorders as mechanisms contributing to the prothrombotic state in polycythemia vera (PV) patients.
• To identify patients with PV, with or without cardiovascular disease (CVD), at high risk for thrombotic events.

Main Methods:

• A cohort of 20 patients was studied, divided into two groups: 10 with PV and 10 with PV and associated CVD (PV+CVD).
• Coagulation profile factors, including Protein S (PS), free fraction, Antithrombin III (AT III), and Protein C (PC), were measured in all participants.

Main Results:

• Significant modifications (p < 0.05) in the levels of the three measured coagulation parameters were observed in both PV and PV+CVD groups.
• Patients in the PV+CVD group exhibited significantly lower levels of these coagulation factors compared to the PV-only group.

Conclusions:

• Changes in coagulation factors contribute to the thrombosis risk in patients with PV syndrome.
• The presence of associated cardiovascular disease in PV patients indicates a more severe thrombotic risk.
• Disorders of coagulation factors represent a major mechanism implicated in the etiology of thrombosis in PV patients, particularly those with CVD.